Features | Partner Sites | Information | LinkXpress
Sign In
Rigel Medical
Schiller
Primedic

Microsensor Measures Intraocular Pressure in Glaucoma

By HospiMedica International staff writers
Posted on 19 Aug 2014
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
An implantable microsensor for wireless intraocular pressure (IOP) measurement allows close monitoring of patients’ disease status and glaucoma therapy success.

The Pro-IOP eye pressure measurement system consists of an implantable microsensor, an external hand held device that telemetrically transfers energy to the microsensor, and a cellular GSM module, which connects with the hand held device to transfer measurement data to a database that can be accessed by clinicians to review the disease status of the patient. Optionally, the patient can also have limited access to the data via an App, in order to review data history or communicate with the ophthalmologist.

The Pro-IOP delivers direct and real IOP, as expressed in mm Hg, which facilitates measurement without disrupting the patient’s lifestyle and without compromising the patient’s behavior. At the same time, the system discloses to clinicians real time, crucial information regarding patient specific pressure fluctuation and variability, shows if the chosen therapeutic measures work, and reports patient therapy adherence. The system is designed for easy patient use and can also be integrated into telemedicine systems for remote patient management.

The Pro-IOP eye pressure measurement system is a product of Implandata Ophthalmic Products (Hannover, Germany). The company has recently reported the successful implantation of the first patient within the ARGOS-02 clinical study, held at Augenklinik Bellevue (Kiel, Germany). In the ARGOS-02 clinical study, six eye centers in Germany are currently recruiting primary open angle glaucoma patients undergoing cataract extraction.

“So far the first results of this innovative product are very compelling,” said Prof. Detlef Uthoff, MD, medical director of Augenklinik Bellevue. “Up to date, early diagnosis and therapeutic management of the disease have been rather dissatisfying for eye doctors. But this innovation allows us for the first time to personalize and control therapy according to the specific needs of the glaucoma patient.”

Related Links:

Implandata Ophthalmic Products
Augenklinik Bellevue



Channels

Women's Health

view channel

Ovary Removal Cuts Breast Cancer Mortality Risk

Women with BRCA-positive breast cancer had a significantly lower risk of dying after prophylactic bilateral oophorectomy, according to a new study. Researchers at McGill University (Montreal, Canada), the Women’s College Research Institute (WCRI; Toronto, ON, Canada), and another 12 institutions conducted a retrospective... Read more

Business

view channel
Image: The Axium Neurostimulator System (Photo courtesy of Spinal Modulation).

St. Jude Medical Completes Acquisition of Spinal Modulation

Global medical device company St. Jude Medical (SJM; St. Paul, MN, USA) has completed the acquisition of Spinal Modulation (Menlo Park, CA, USA), developer of the Axium neurostimulator system.... Read more
 

Events

23 May 2015 - 25 May 2015
27 May 2015 - 29 May 2015
30 May 2015 - 02 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.